Humoral complementomics – exploration of noninvasive complement biomarkers as predictors of renal cancer progression

References

• Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, et Roumenina LT. Complement system part II: role in immunity. Front Immunol. 2015;6:257. doi:10.3389/fimmu.2015.00257.
   PubMed Web of Science ®Google Scholar
• Roumenina LT, Daugan MV, Petitprez F, Sautès-Fridman C, et Fridman WH. Context-dependent roles of complement in cancer. Nat Rev Cancer. 2019 déc;19(12):698–14. doi:10.1038/s41568-019-0210-0.
   PubMed Web of Science ®Google Scholar
• Revel M, Daugan MV, Sautés-Fridman C, Fridman WH, et Roumenina LT. Complement system: promoter or suppressor of cancer progression?. Antibodies (Basel). 2020 oct;9(n^o 4):E57. doi:10.3390/antib9040057.
   PubMedGoogle Scholar
• Roumenina LT, Daugan MV, Noé R, Petitprez F, Vano YA, Sanchez-Salas R, Becht E, Meilleroux J, Clec’h BL, Giraldo NA, et al. Tumor cells hijack macrophage-produced complement C1q to promote tumor growth. Cancer Immunol Res. 2019 juill;7(n^o 7):1091–1105. doi:10.1158/2326-6066.CIR-18-0891.
   PubMed Web of Science ®Google Scholar
• Daugan MV, Revel M, Russick J, Dragon-Durey M-A, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, et al. Complement C1s and C4d as prognostic biomarkers in renal cancer: emergence of non-canonical functions of C1s. Cancer Immunol Res. 2021 mai;9(8):891–908. doi:10.1158/2326-6066.CIR-20-0532.
   PubMed Web of Science ®Google Scholar
• Daugan MV, Revel M, Thouenon R, Dragon-Durey M-A, Robe-Rybkine T, Torset C, Merle NS, Noé R, Verkarre V, Oudard SM, et al. Intracellular factor H drives tumor progression independently of the complement cascade. Cancer Immunol Res. 2021;9(8):909–925. mai. doi:10.1158/2326-6066.CIR-20-0787.
   PubMed Web of Science ®Google Scholar
• Ajona D, Okrój M, Pajares MJ, Agorreta J, Lozano MD, Zulueta JJ, Verri C, Roz L, Sozzi G, Pastorino U, et al. Complement C4d-specific antibodies for the diagnosis of lung cancer. Oncotarget. 2018 janv;9(5):6346–6355. doi:10.18632/oncotarget.23690.
   PubMedGoogle Scholar
• Klikovits T, Stockhammer P, Laszlo V, Dong Y, Hoda MA, Ghanim B, Opitz I, Frauenfelder T, Nguyen-Kim TDL, Weder W, et al. Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Sci Rep. 2017 nov;7(n^o 1 Art.):16456. doi:10.1038/s41598-017-16551-7.
   PubMedGoogle Scholar
• Amornsiripanitch N, Hong S, Campa MJ, Frank MM, Gottlin EB, et Patz EF. Complement factor H autoantibodies are associated with early stage NSCLC. Clin Cancer Res. 2010 juin;16(12):3226–3231. doi:10.1158/1078-0432.CCR-10-0321.
   PubMed Web of Science ®Google Scholar
• Bushey RT, Moody MA, Nicely NL, Haynes BF, Alam SM, Keir ST, Bentley RC, Roy Choudhury K, Gottlin EB, Campa MJ, et al. A therapeutic antibody for cancer, derived from single human B cells. Cell Rep. 2016 17;15(7):1505–1513. doi:10.1016/j.celrep.2016.04.038.
   PubMed Web of Science ®Google Scholar
• Campa MJ, Gottlin EB, Bushey RT, et Patz EF. Complement factor H antibodies from lung cancer patients induce complement-dependent lysis of tumor cells, suggesting a novel immunotherapeutic strategy. Cancer Immunol Res. 2015 déc.;3(12):1325–1332. doi:10.1158/2326-6066.CIR-15-0122.
   PubMed Web of Science ®Google Scholar
• King BC, Kulak K, Krus U, Rosberg R, Golec E, Wozniak K, Gomez MF, Zhang E, O’Connell DJ, Renström E, et al. Complement component C3 is highly expressed in human pancreatic islets and prevents β cell death via ATG16L1 interaction and autophagy regulation. Cell Metab. 2019 janv.;29(1):202–210.e6. doi:10.1016/j.cmet.2018.09.009.
   PubMed Web of Science ®Google Scholar
• Niyonzima N, Rahman J, Kunz N, West EE, Freiwald T, Desai JV, Merle NS, Gidon A, Sporsheim B, Lionakis MS, et al. Mitochondrial C5aR1 activity in macrophages controls IL-1β production underlying sterile inflammation. Sci Immunol. 2021 déc.;6(66):eabf2489. doi:10.1126/sciimmunol.abf2489.
   PubMed Web of Science ®Google Scholar
• Yan B, Freiwald T, Chauss D, Wang L, West E, Mirabelli C, Zhang CJ, Nichols E-M, Malik N, Gregory R, et al. SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Sci Immunol. 2021 avr.;6(58):eabg0833. doi:10.1126/sciimmunol.abg0833.
   PubMed Web of Science ®Google Scholar
• Vasilev VV, Noe R, Dragon-Durey M-A, Chauvet S, Lazarov VJ, Deliyska BP, Fremeaux-Bacchi V, Dimitrov JD, Roumenina LT. Functional characterization of autoantibodies against complement component C3 in patients with lupus nephritis. J Biol Chem. 2015 oct;290(42):25343–25355. doi:10.1074/jbc.M115.647008.
   PubMed Web of Science ®Google Scholar
• Vasilev V, Artero MR, Petkova M, Mihaylova G, Dragon-Durey M-A, Radanova M, Roumenina LT. Clinical relevance of anti-C3 and anti-C4 autoantibodies in lupus nephritis. Kidney Int Reports. 2024. doi:10.1016/j.ekir.2024.01.052.
   Google Scholar
• Marinozzi MC, Roumenina LT, Chauvet S, Hertig A, Bertrand D, Olagne J, Frimat M, Ulinski T, Deschênes G, Burtey S, et al. Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. J Am Soc Nephrol. 2017;28(5):1603–1613. mai. doi:10.1681/ASN.2016030343.
   PubMed Web of Science ®Google Scholar
• Chauvet S, Berthaud R, Devriese M, Mignotet M, Vieira Martins P, Robe-Rybkine T, Miteva MA, Gyulkhandanyan A, Ryckewaert A, Louillet F, et al. Anti-factor B antibodies and acute postinfectious GN in children. J Am Soc Nephrol. 2020 avr.;31(4):829–840. doi:10.1681/ASN.2019080851.
   PubMed Web of Science ®Google Scholar
• Meuleman M-S, Duval A, Grunenwald A, Rezola Artero M, Dermani M, Peliconi J, Revel M, Vieira-Martins P, Courbebaisse M, Parfait B, et al. Usefulness and analytical performances of complement multiplex assay for measuring complement biomarkers in plasma. Clin Chim Acta. 2024 févr.;554:117750. doi:10.1016/j.cca.2023.117750.
   PubMed Web of Science ®Google Scholar
• Hurler L, Toonen EJM, Kajdácsi E, van Bree B, Brandwijk RJMGE, de Bruin W, Lyons PA, Bergamaschi L, Sinkovits G, Cervenak L, et al. Distinction of early complement classical and lectin pathway activation via quantification of C1s/C1-INH and MASP-1/C1-INH complexes using novel ELISAs. Front Immunol. 2022;13:1039765. doi:10.3389/fimmu.2022.1039765.
   PubMed Web of Science ®Google Scholar
• Uzonyi B, Szabó Z, Trojnár E, Hyvärinen S, Uray K, Nielsen HH, Erdei A, Jokiranta TS, Prohászka Z, Illes Z, et al. Autoantibodies against the complement regulator factor H in the serum of patients with neuromyelitis optica spectrum disorder. Front Immunol. 2021;12:660382. doi:10.3389/fimmu.2021.660382.
   PubMed Web of Science ®Google Scholar
• Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc. 1996;58(1):267–288. doi:10.1111/j.2517-6161.1996.tb02080.x.
   Google Scholar
• Simon N, Friedman J, Hastie T, et Tibshirani R. Regularization Paths for Cox’s Proportional Hazards Model via Coordinate Descent. J Stat Softw. 2011 mars;39(5):1–13. doi:10.18637/jss.v039.i05.
   PubMed Web of Science ®Google Scholar
• Reese B, Silwal A, Daugherity E, Daugherity M, Arabi M, Daly P, Paterson Y, Woolford L, Christie A, Elias R, et al. Complement as prognostic biomarker and potential therapeutic target in renal cell carcinoma. J Immunol. 2020 déc.;205(11):3218–3229. doi:10.4049/jimmunol.2000511.
   PubMed Web of Science ®Google Scholar
• Cooley LS, Rudewicz J, Souleyreau W, Emanuelli A, Alvarez-Arenas A, Clarke K, Falciani F, Dufies M, Lambrechts D, Modave E, et al. Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression. Mol Cancer. 2021 oct.;20(n^o 1):136. doi:10.1186/s12943-021-01416-5.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jiang H, Xu G, Wen H, Gu B, Liu J, Mao S, Na R, Jing Y, Ding Q, et al. Proteins S100A8 and S100A9 are potential biomarkers for renal cell carcinoma in the early stages: results from a proteomic study integrated with bioinformatics analysis. Mol Med Rep. 2015 juin;11(6):4093–4100. doi:10.3892/mmr.2015.3321.
   PubMed Web of Science ®Google Scholar
• Daugan MV, Revel M, Lacroix L, Sautès-Fridman C, Fridman WH, et Roumenina LT. Complement detection in human tumors by immunohistochemistry and immunofluorescence. Methods Mol Biol. 2021;2227:191–203. doi:10.1007/978-1-0716-1016-9_18.
   PubMedGoogle Scholar
• M M, Smoląg KI, Björk A, Gullstrand B, Okrój M, Leffler J, Jönsen A, Bengtsson AA, Blom AM. Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus. Arthritis Res Ther. 2017 juin;19(n^o 1). doi:10.1186/s13075-017-1470-2.
   Google Scholar
• Kraaij T, Nilsson SC, van Kooten C, Okrój M, Blom AM, et Teng YO. Measuring plasma C4D to monitor immune complexes in lupus nephritis, Lupus Sci Med, vol. 6, n^o 1, p. e000326, 2019, doi: 10.1136/lupus-2019-000326.
   PubMed Web of Science ®Google Scholar
• Kajdácsi E, Jandrasics Z, Veszeli N, Makó V, Koncz A, Gulyás D, Köhalmi KV, Temesszentandrási G, Cervenak L, Gál P, et al. Patterns of C1-Inhibitor/Plasma serine protease complexes in healthy humans and in hereditary angioedema patients. Front Immunol. 2020;11:794. doi:10.3389/fimmu.2020.00794.
   PubMed Web of Science ®Google Scholar
• Bushey RT, Gottlin EB, Campa MJ, et Patz EF Jr. Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis. PloS One. 2021 juin;16(n^o 6):e0252577. doi:10.1371/journal.pone.0252577.
   PubMed Web of Science ®Google Scholar
• Vasilev VV, Radanova M, Lazarov VJ, Dragon-Durey M-A, Fremeaux-Bacchi V, et Roumenina LT. Autoantibodies against C3b-functional consequences and disease relevance. Front Immunol. 2019;10:64. doi:10.3389/fimmu.2019.00064.
   PubMed Web of Science ®Google Scholar
• Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015 mai;521(7550):94–98. doi:10.1038/nature14395.
   PubMed Web of Science ®Google Scholar
• Teillaud J-L et Dieu-Nosjean M-C. Intratumoral plasma cells: more than a predictive marker of response to anti-PD-L1 treatment in lung cancer?. Cancer Cell. 2022 mars;40(3):240–243. doi:10.1016/j.ccell.2022.02.008.
   PubMed Web of Science ®Google Scholar
• Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, Costich TL, Moran C, Harro CM, Rigolizzo KE, et al. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature. 2021 mars;591(7850):464–470. doi:10.1038/s41586-020-03144-0.
   PubMed Web of Science ®Google Scholar
• Mandal G, Biswas S, Anadon CM, Yu X, Gatenbee CD, Prabhakaran S, Payne KK, Chaurio RA, Martin A, Innamarato P, et al. IgA-dominated humoral immune responses govern patients’ outcome in endometrial cancer. Cancer Res. 2022 mars;82(5):859–871. doi:10.1158/0008-5472.CAN-21-2376.
   PubMed Web of Science ®Google Scholar
• Juranić Z, Stanojević-Bakić N, Maletić V, et Borkovacki R. Immune reactive proteins in renal cell carcinoma patients treated by IFN alpha alone or in combination with vinblastine, Neoplasma, vol. 41, n^o 4, p. 229–232, 1994.
   PubMed Web of Science ®Google Scholar
• Magyarlaki T, Kiss B, Buzogány I, Fazekas A, Sükösd F, et Nagy J. Renal cell carcinoma and paraneoplastic IgA nephropathy. Nephron. 1999 juin;82(n^o 2):127–130. doi:10.1159/000045388.
   PubMed Web of Science ®Google Scholar
• Netti GS, Lucarelli G, Spadaccino F, Castellano G, Gigante M, Divella C, Rocchetti MT, Rascio F, Mancini V, Stallone G, et al. PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. Aging (Albany NY). 2020 avr.;12(8):7585–7602. doi:10.18632/aging.103169.
   PubMedGoogle Scholar
• Blok VT, Daha MR, Tijsma OM, Weissglas MG, van den Broek LJ, et Gorter A. A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Lab Invest. 2000 mars;80(3):335–344. doi:10.1038/labinvest.3780038.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Netti GS, Rutigliano M, Lasorsa F, Loizzo D, Milella M, Schirinzi A, Fontana A, Di Serio F, Tamma R, et al. MUC1 expression affects the immunoflogosis in renal cell carcinoma microenvironment through complement system activation and immune infiltrate modulation. Int J Mol Sci. 2023 mars;24(5):4814. doi:10.3390/ijms24054814.
   PubMed Web of Science ®Google Scholar